News
HROW
10.00
-2.63%
-0.27
Press Release: Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024 Company to Host Conference Call to Discuss Results at 8:00 a.m. ET on May 14, 2024. Harrow is a leading U.S. Eyecare pharmaceutical company. The Company will release its financial results for the first quarter ended March 31, 2024, after the market close. The company will host a conference call and live webcast to discuss the results and provide a business update.
Dow Jones · 23h ago
Around $2M Bet On This Industrial Stock? Check Out These 3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates confidence in the company’s prospects or that they view the stock as a bargain. U.S. Stocks closed mixed on Wednesday. There were a few notable insider trades. Northern Technologies International Corporation and Harrow, Inc. Made notable purchases.
Benzinga · 23h ago
Over $24M Bet On RXO? Check Out These 3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates confidence in the company’s prospects or that they view the stock as a bargain. RXO, Inc. And Harrow Inc. Made notable insider purchases on Friday. Sunoco LP made a purchase of 1,500 shares of Sunoco.
Benzinga · 3d ago
Weekly Report: what happened at HROW last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at HROW last week (0408-0412)?
Weekly Report · 04/15 11:55
HROW, HCAT and EGRX are among after hour movers
On the Move HROW, HCAT and EGRX are among after hour movers. Eagle Pharmaceuticals (EGRX) is down 10%. Applied Optoelectronics (AAOI) and Harrow (HROW) are among the gainers.
Seeking Alpha · 04/12 21:05
Harrow Health Price Target Announced at $24.00/Share by Craig-Hallum
Dow Jones · 04/11 16:43
Harrow Health Initiated at Buy by Craig-Hallum
Dow Jones · 04/11 16:43
Craig-Hallum Initiates Coverage On Harrow with Buy Rating, Announces Price Target of $24
Benzinga · 04/11 16:32
HARROW, INC. <HROW.O> : CRAIG-HALLUM INITIATES COVERAGE WITH BUY RATING AND TARGET PRICE $24
Reuters · 04/11 11:17
U.S. RESEARCH ROUNDUP-Airbnb, Albemarle, Biogen
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Airbnb, Albemarle and Biogen among those with revised targets. AIG, Aflac and Allstate among companies with new targets for the day. Analysts cut target prices on some of the companies.
Reuters · 04/11 07:32
Weekly Report: what happened at HROW last week (0401-0405)?
Weekly Report · 04/08 12:01
Analysts Offer Insights on Healthcare Companies: Lonza Group Ltd (Six Swiss: CH:LONN), Harrow Health (HROW) and Innoviva (INVA)
TipRanks · 04/03 09:04
MELT PHARMACEUTICALS CLOSES $24 MILLION SERIES B PREFERRED STOCK FINANCING
Reuters · 04/02 12:16
Weekly Report: what happened at HROW last week (0325-0329)?
Weekly Report · 04/01 11:58
Weekly Report: what happened at HROW last week (0318-0322)?
Weekly Report · 03/25 12:02
Harrow Health’s Growth Trajectory: A Buy Rating Amid Strong Product Performance and Strategic Market Investments
TipRanks · 03/21 16:45
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Lifecore Biomedical, Inc. Dipped 31.7% to $4.91 on Wednesday. ETAO International Co., Ltd. Shares shot up 111.5% after the company announced a reverse stock split. NuScale Power Corporation shares tumbled around 35% after spiking 17% on Tuesday.
Benzinga · 03/20 18:03
Stocks Muted as Fed Rate Decision Looms, Micron Earnings on Tap
NASDAQ · 03/20 14:08
INTC Stock Alert: Intel Just Got a Major $8.5 Billion Boost
Department of Commerce has a preliminary agreement with Intel to provide $8.5 billion in funding for the development of new facilities in Arizona, Ohio, New Mexico and Oregon. INTC stock is up 2.7% as of Wednesday morning. Up Fintech Holding, Aquestive Therapeutics and Harrow stock are also moving today.
Investorplace · 03/20 13:06
More
Webull provides a variety of real-time HROW stock news. You can receive the latest news about Harrow Health Inc through multiple platforms. This information may help you make smarter investment decisions.
About HROW
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.